Posted On: 09/11/2014 10:25:52 AM
Post# of 22855
Wells Fargo maintained an Outperform rating on Orexigen Therapeutics (NASDAQ: OREX) and raised its price target to $14-$15 (from $11-$12). Earlier Takeda Pharmaceuticals and Orexigen Therapeutics jointly announced that the FDA has approved Contrave extended-release tablets for chronic weight management.
Analyst Matthew J. Andrews expects a stronger launch than VIVUS (NASDAQ: VVUS) in 2012 and Arena Pharma (NASDAQ: ARNA) in 2013. He also said likelihood of CHMP recommendation for approval has increased.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $5.90 yesterday.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼
